IDP Pharma and BCN Peptides engage in the development of a new chemical entity aimed to treat Multiple Myeloma. The collaborative project has been granted with funds from the European Union FEDER via ACCIO and its programme “Nuclis d’Innovació Tecnológica”.
IDP Pharma will attend next BIO-Europe spring, Europe’s largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies. It is regarded as a “must attend” event for the biotech industry. This event will take place in Barcelona from 20-22 March 2017.
IDP Pharma has closed a 1,4M€ seed investment round, following a pre-seed round of 0,1M€ (June 2015) , which adds to the 1,2M€ funds granted by several public institutions (MINECO, ENISA, CDTI-NEOTEC and ACCIÓ).
The company will allocate the capital to advance the preclinical development of its first products for two cancer indications, to set up new discovery programs, and to continue developing its technology: IDP-Platform.
IDP Pharma will attend next Bio International Convention 2016 in San Francisco, the world’s largest biotechnology event. The BIO attracts over 15,000 biotechnology and pharma leaders who come together for one week of intensive networking and partnering meetings to discover new opportunities and promising partnerships. You will find partnering opportunities, an outstanding education program, an expansive exhibition floor, and exclusive networking events where you will access over 2,500 CEO’s from leading biotech companies.
IDP Pharma has filed a patent application (product and use) of a new chemical entity for cancer treatment obtained from IDP-Platform.
IDP Pharma will attend next JP Morgan Healthcare Conference 2016. This event will take place in San Francisco, CA from January 11-14, 2016. If you are interested in meeting IDP Pharma delegates and knowing more about IDP’s current programs, send an email to firstname.lastname@example.org to arrange a meeting.
IDP Pharma has closed its first investment round. The funds raised will allow the company to develop its technology and deliver first active compounds against an IDP, a novel class of therapeutic targets.
IDP Pharma will attend next Bio International Convention in Philadelphia, the world’s largest biotechnology gathering. It allows exhibitors to reach high-level executives and influential decision makers who come to BIO to discover new players in the industry, form partnerships and evaluate emerging technologies.
The BIO Convention will host thousands of organizations including the leading biotech companies, top 25 pharma companies, top 20 CROs and CMOs, more than 300 academic institutions including the major research labs and government agencies and the leading consultants and service companies.
IDP Pharma has stablished its headquarters at the Parc Científic de Barcelona (PCB).
The Parc Científic de Barcelona offers institutions and companies an ideal environment dedicated to the generation, transfer and addition of value in the field of the life sciences, with state-of-the-art facilities for drug discovery.
IDP Pharma participated in BioEmprenedorXXI (7th edition), a program to support entrepreneurship in the field of life sciences in its broadest sense: biotechnology, biomedicine, medical technologies and agri-food sector.